TScan Therapeutics, Inc.
NASDAQ:TCRXBiotechnology
+$0.02 today
- Market cap
- $50.37M
- Beta
- 1.03
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.96
Volume 0.00M
Average 0.81M
TCRX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
TScan Therapeutics, Inc.NASDAQ: TCRX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$27.28M, compared with -$32.77M a year earlier. Trailing-twelve-month EBITDA was -$118.65M.
Context
- EBITDA amounted to 1202.2% of revenue in FY2025, down 3049.8 pp from a year earlier.
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$7.56M (+93.9%) for the fiscal year ending Dec 2026, a step up from the -3.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$27.28M-26.6% QoQ
- Last fiscal yearDec 2025
- -$124.13M-3.7% YoY
- LTMMar 2026
- -$118.65M+4.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +16.7% | +94.7% | +78.0 pp |
| 1 year | -3.7% | +93.9% | +97.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (124.13M) USD
- Year-over-year change
- -3.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (124.13M) | -3.7% |
| FY2024 | 2024-12-31 | (119.74M) | -49.5% |
| FY2023 | 2023-12-31 | (80.1M) | -33.7% |
| FY2022 | 2022-12-31 | (59.91M) | -32.3% |
| FY2021 | 2021-12-31 | (45.3M) | — |
EBITDA vs competitors
How TCRX compares with its peers on the latest reported figures
- TCRX's LTM Mar 2026 EBITDA of -$118.65M is the lowest of the 10 companies compared; the peer median is -$58.88M.
- Its year-over-year change of +4.8% is the 5th highest of 10, against a peer median of +0.7%.
- EBITDA amounts to 1298.7% of revenue for TCRX, versus a peer median of 223.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $148.02M | +264.5% | — | 223.7% | |
| LTM Mar 2026 | $47.3M | +203.4% | — | 18.5% | |
| LTM Apr 2026 | -$7.89M | +18.5% | — | 437.7% | |
| LTM Mar 2026 | -$38.33M | -3.1% | — | — | |
| LTM Mar 2026 | -$58.88M | -297.6% | — | — | |
| LTM Mar 2026 | -$78.19M | +0.2% | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$82.08M | +0.7% | — | — |
| LTM Mar 2026 | -$102.73M | +7.3% | — | — | |
| LTM Mar 2026 | -$104.13M | -8.2% | — | — | |
| LTM Mar 2026 | -$118.65M | +4.8% | — | 1298.7% | |
| Peer median (excluding TCRX) | -$58.88M | +0.7% | — | 223.7% | |
Competitors are the stored peer set for TCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.14M | 13.54M | 21.05M | 2.82M | 10.33M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.87M |
| Gross Profit | 10.14M | 13.54M | 21.05M | 2.82M | 7.46M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 72.2% |
| Research & Development | 44.95M | 59.82M | 88.15M | 107.35M | 114.15M |
| Selling, General & Admin | 13.83M | 20.35M | 25.49M | 29.56M | 31.99M |
| Operating Expenses | 58.78M | 80.17M | 114.51M | 137.64M | 143.27M |
| Depreciation & Amortization | 3.33M | 5.14M | 5.36M | 4.11M | 2.87M |
| EBITDA | (45.3M) | (59.91M) | (80.1M) | (119.74M) | (124.13M) |
| EBITDA Margin | -446.7% | -442.6% | -380.5% | -4252.1% | -1202.2% |
| Operating Income | (48.64M) | (66.64M) | (93.46M) | (134.82M) | (135.81M) |
| Operating Margin | -479.6% | -492.3% | -444.0% | -4787.7% | -1315.4% |
| Interest Income | 16K | 1.59M | 8M | 12.07M | 8.82M |
| Interest Expense | 0 | 1.18M | 3.76M | 3.65M | 2.77M |
| Other Income / Expenses | 16K | 415K | 4.24M | 7.32M | 6.05M |
| Income Before Tax | (48.63M) | (66.22M) | (89.22M) | (127.5M) | (129.77M) |
| Pre-Tax Margin | -479.5% | -489.3% | -423.9% | -4527.7% | -1256.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (48.63M) | (66.22M) | (89.22M) | (127.5M) | (129.77M) |
| Net Margin | -479.5% | -489.3% | -423.9% | -4527.7% | -1256.8% |
| EPS (Basic) | (2.03) | (2.74) | (1.36) | (1.14) | (1.00) |
| EPS (Diluted) | (2.03) | (2.74) | (1.36) | (1.14) | (1.00) |
| Weighted Avg Shares | 23.91M | 24.05M | 65.6M | 111.99M | 129.86M |
| Weighted Avg Shares (Diluted) | 23.91M | 24.05M | 65.6M | 111.99M | 129.86M |
TScan Therapeutics, Inc.
NASDAQ:TCRX
Intrinsic Alpha fair value
Locked
Current Price
$0.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.